-- SSYグループ（香港証券取引所：2005）のC反応性タンパク質および血清アミロイドA/C反応性タンパク質の包括的な検査キットが、中国河北省薬品監督管理局から医療機器登録証明書を取得したことが、水曜日に香港証券取引所に提出された書類で明らかになった。 このキットは、ヒト血清、血漿、または全血サンプル中のC反応性タンパク質および血清アミロイドAのレベルを体外で定量的に検出するために使用される。
Related Articles
Mining & Metals
Earnings Flash (CFP.TO) Canfor Reports Q1 Revenue $1.36B, vs. $1.418M a Year Earlier
$CFP.TO
Research
BTIG Downgrades Embecta to Neutral From Buy
Embecta (EMBC) has an average rating of hold and mean price target of $8, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$EMBC
Mining & Metals
TELUS Digital Expands in Asia-Pacific and Argentina to Support Growing Demand for AI Data Services and Digital Customer Experience
TELUS' (T.TO, TU) global technology division, TELUS Digital, "significantly" expanded its global delivery footprint for AI-powered CX, AI data services, and trust and safety solutions over the last nine months, it said on Wednesday.This growth, the company said, "strengthens" TELUS Digital's presence across the Asia-Pacific region, including Indonesia, Thailand, Vietnam and Malaysia, and extends its reach in Latin America with a new location in Argentina.The company has also expanded two existing sites in Bengaluru and Ahmedabad, India, and added a new site in Kolkata, bringing its presence in the country to eight sites across six cities.U.S.-listed shares of TELUS were last seen down 0.3% at US$12.56 in pre-market trading.
$T.TO